{"pub": "marketwatch", "url": "https://marketwatch.com/articles/biogen-stock-soars-on-return-of-alzheimers-drug-51571746988", "downloaded_at": "2019-10-22 15:09:16.963673+00:00", "title": "Biogen Stock Is Soaring as Hope Returns for Alzheimer\u2019s Drug", "language": "en", "text": "Biogen shares were 28% higher on Tuesday after the company stunned investors with news that it planned to submit for Food and Drug Administration approval the experimental Alzheimer\u2019s drug that appeared to fail in clinical trials earlier this year.\n\nThe failure of the drug, called aducanumab, cut Biogen\u2019s share price by 29% in a single day in March. The stock had not recovered as of Monday. Aducanumab\u2019s failure dominated investor sentiment around Biogen (BIIB), sparked broader worries about the broader biotech sector, and...", "description": "When the experimental drug for Alzheimer\u2019s, aducanumab, appeared to fail in March, it sent Biogen\u2019s stock plunging and sparked concerns about the biotech sector. Now, the drug\u2019s return has raised hopes -- and questions.", "authors": ["Josh Nathan-Kazis"], "top_image": "https://asset.barrons.com/public/resources/images/ON-CZ623_Biogen_OR_20190502101402.jpg", "published_at": "2019-10-22"}